Eli Lilly's Q2 2026 revenue rose 48% to $23 billion on surging Mounjaro and Zepbound sales, and the company raised full-year guidance to $85 billion-$87 billion. The quarter also set up a crowded 12 months ahead: broad direct-to-consumer marketing for the oral GLP-1 pill Foundayo is underway, and…
Eli Lilly reported second-quarter 2026 revenue of $23 billion, up 48 percent year over year, on surging sales of Mounjaro and Zepbound . Mounjaro, Lilly's type 2 diabetes brand, generated $9.9 billion in quarterly sales, up 91 percent from the same period a year earlier. Zepbound, the company's obesity brand, brought in $5 billion, up 46 percent. Together they contributed $14.9 billion, more than half of the quarter's total revenue, or about 65 percent. Both drugs are formulations of tirzepatide, a peptide that activates the GIP and GLP-1 receptors.
Chief Financial Officer Lucas Montarce said Lilly products accounted for 60 to 70 percent of GLP-1 prescriptions in the second quarter. That is the CFO's assertion from the company's earnings presentation, and it was not independently verified. It implies that much of the remaining 30 to 40 percent of the class belongs to Novo Nordisk, whose Ozempic and Wegovy are the other major products in the category.
On August 5, 2026, Lilly raised its full-year 2026 revenue guidance to $85 billion to $87 billion, from a prior range of $82 billion to $85 billion. The top end of the range moved up by $2 billion, and the midpoint moved from $83.5 billion to $86 billion. The revision is a forecast, not a result, but its direction signals how Lilly's executives, led by Chairman and CEO Dave Ricks, read demand for the rest of the year. As with all company disclosures cited here, the revenue, prescription-share, and efficacy figures came from Lilly's statements and were not independently verified.
The same quarterly report frames the next stage of the pipeline. Retatrutide , an investigational peptide also known as LY3437943, activates three receptors: GIP, GLP-1, and glucagon. That puts it a step beyond the dual-agonist tirzepatide platform behind Mounjaro and Zepbound, and beyond semaglutide, the GLP-1 receptor agonist in Ozempic and Wegovy.
The design rationale follows from the pharmacology. GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central pathways. GIP receptor activation adds insulinotropic signaling and is thought to influence how adipose tissue handles energy. Glucagon receptor activation, in the presence of the other two, is believed to increase energy expenditure; on its own it would raise blood glucose, so the triple agonist is an attempt to keep glucose stable while pushing metabolism harder. Whether that balance holds at weight-loss doses is the central question of the program.
Dr. Dan Skovronsky, Lilly's chief scientific and product officer, said retatrutide has produced a magnitude of weight loss not previously seen in patients with diabetes and obesity. That is an executive characterization; Lilly has not published the quantitative trial results behind it. The company describes itself as deep into the clinical program and hopes to submit retatrutide to the U.S. Food and Drug Administration FDA in 2027.
During the week of August 3, 2026, Lilly said it would offer early access to retatrutide for eligible patients outside the trials. A company spokesperson said the program would cover a "limited number of patients who meet specific medical criteria." The criteria have not been disclosed, nor has the legal basis for the arrangement. Early access is a separate channel from FDA review: it allows use before approval under defined conditions, and it does not shorten the regulatory timeline or lower the evidence bar.
Early-access arrangements have been more common in oncology than in metabolic disease, where the potentially eligible population is enormous if the criteria are drawn broadly. That tension is visible in the two routes now on the table. The NIH request concerned one named patient; the company's program contemplates an unspecified number of patients meeting undisclosed criteria. Without those criteria public, outside observers cannot tell whether the program is a narrow bridge for patients with no remaining options or a broader pre-approval distribution.
In April 2026, Lilly launched Foundayo , its oral GLP-1 pill. Broad direct-to-consumer marketing began in June 2026, roughly two months after launch. The speed of that ramp signals how much the company is investing in the oral segment, where the value proposition is simple: a pill removes the injection barrier that keeps many patients with obesity or type 2 diabetes from starting or continuing treatment.
Peptides do not survive the gut well. Gastric acid and intestinal proteases degrade them, and their size and polarity block passive absorption across the intestinal wall. That is why nearly every GLP-1 product on the market is an injection, and why the oral formulations that preceded Foundayo carried strict fasting requirements around dosing. Delivering a peptide by mouth at reproducible exposures requires formulation technology that is still relatively new.
Lilly's advertising asserts that Foundayo is the only GLP-1 pill that can be taken any time of day. That is an advertising claim and has not been independently verified. Lilly has not disclosed the active pharmaceutical ingredient in Foundayo, so outside scientists cannot yet assess its stability, bioavailability, or exposure profile against the injected products. If the convenience claim holds, it would matter for adherence; dosing burden and gastrointestinal side effects are the class's best-known barriers to staying on treatment.
In April 2026, the same month Foundayo launched, a clinician at the National Institutes of Health requested special access to retatrutide for one patient, who was 79 years old. The request shows how far demand for the investigational peptide has reached: a government physician sought the drug for an individual older patient months before Lilly disclosed its own early-access plan.
The patient's age, combined with the political profile of the request, produced immediate speculation that the patient was Donald Trump, who was then 79 years old and a former U.S. president. The White House denied the allegations. The patient's identity has not been disclosed, and the denial leaves the question open; it establishes only that the White House disputes the claim.
Special access is the general term for the mechanisms by which investigational drugs reach individual patients outside clinical trials in the United States, typically in serious conditions with no comparable treatment options. The details of this request, including the patient's condition and the reviews it underwent, have not been made public. What is clear is that the two channels are distinct: the NIH request originated with a government clinician for a single patient, while Lilly's later program is a corporate decision about a broader, still undefined population. Neither route is an approval, and neither alters the fact that retatrutide's safety and efficacy are still being established in trials.
The Peptide Atlas registry for retatrutide lists 33 registered clinical trials. The phase breakdown on file is 6 Phase 3, 3 Phase 1, and 1 Phase 2. The status breakdown is 4 recruiting, 4 active, and 2 completed. A program with six Phase 3 registrations is one preparing for registration, and the mix of indications shows the molecule is being studied well beyond obesity. The Peptide Atlas reference page for retatrutide, at https://peptideatlas.co/peptides/retatrutide, consolidates the trial registry, indexed literature, and purity records.
The notable registrations include:
Obesity and overweight appear in four of the six listed trials, but the program also reaches into type 2 diabetes, steatotic liver disease, and chronic low back pain. The back pain trial signals an interest in musculoskeletal outcomes that are often secondary in GLP-1 studies. The master protocol design of SYNERGY-Outcomes lets Lilly test multiple agents against a shared control infrastructure, which can accelerate readouts when several candidates are in play.
Peptide Atlas indexes 71 PubMed papers on retatrutide. The most consequential recent publication is the Phase 3 TRANSCEND-T2D-1 trial, published in The Lancet on June 6, 2026: a double-blind, randomized study of retatrutide in people with type 2 diabetes and inadequate glycemic control with diet and exercise PMID 42250575 . A systematic review and meta-analysis of retatrutide's effects on blood pressure and lipid levels was published in High Blood Pressure and Cardiovascular Prevention on June 29, 2026 PMID 42371360 . A broader meta-analysis of incretin-based therapies and blood pressure appeared in the European Journal of Preventive Cardiology on May 15, 2026 PMID 40899050 .
The laboratory literature is active on two fronts. A study in Behavioural Brain Research, dated July 1, 2026, examined retatrutide's effects on learning and memory in streptozotocin-induced diabetic rats PMID 42385950 , an indication of the central nervous system questions the molecule raises. And an Organic Letters paper, published June 1, 2026, described a hydrophobic tag-assisted liquid-phase strategy for synthesizing retatrutide PMID 42224238 . The synthesis work matters because the peptide's commercial future depends on manufacturing at scale.
The record also shows what is not yet established. TRANSCEND-T2D-1 addresses glycemic control; the headline claim about weight loss of a magnitude not previously seen has no published quantitative counterpart in the indexed literature as of the dataset date. The design, sample size, duration, and endpoints of the obesity trials have not been fully disclosed by Lilly, and the eligibility criteria for the early-access program remain unspecified.
The financial layer is the firmest part of this story. The revenue and sales figures are company-reported but concrete, and the arithmetic is straightforward: two products, $14.9 billion combined, in a $23 billion quarter. The prescription-share number is a different kind of claim. Montarce's 60 to 70 percent is an executive estimate of a market that no single source fully measures, and it should be read as an estimate.
The efficacy claim for retatrutide is thinner still. Skovronsky's description of the weight-loss result is an executive characterization, with trial details not provided. The Foundayo "any time of day" claim is an advertising assertion. Neither has been tested by an independent body or published in a form that outside researchers could scrutinize.
What remains unresolved:
Peptides referenced: Semaglutide, Tirzepatide, Retatrutide, Glucagon, GLP-1.
Related reading: GLP-1 users double per household, Lilly beats forecasts as Mounjaro, Zepbound drive 48% revenue surge, On a GLP-1? Exclusive Report Says There's a Vacation for That, How Do GLP-1s Change Brain Signaling?.